PAXLOVID REBOUND COVID PHENOMENA; the FDA knew and Pfszier knew, as usual they lied and have no concern about safety, JUST money$$$$$, everyone is into making money, see this information

by Paul Alexander

There is no long-term safety data for Paxlovid; There are limited clinical data available; Serious & unexpected adverse events may occur that have not been previously reported with PAXLOVID

Key information:

  • ‘There are limited clinical data available for PAXLOVID. Serious and unexpected adverse events may occur that have not been previously reported with PAXLOVID use.

  • The concomitant use of PAXLOVID and certain other drugs may result in potentially significant drug interactions.

  • Hypersensitivity and anaphylactic reactions have been reported with PAXLOVID.

  • Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir.

  • PAXLOVID may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

  • Carcinogenicity studies have not been conducted with nirmatrelvir.

COVID Rebound After Paxlovid 

A pre-print study7 was published describing this rebound phenomenon in a patient who had been treated with Paxlovid. A fully vaccinated and boosted 71-year-old male had a high exposure to COVID with symptoms.   Day 0 he began a course of Paxlovid. His symptoms quickly and completely resolved by Day 2.

While continuing to isolate, the patient’s symptoms returned on Day 9 and peaked on Day 10. Viral antigen testing was conducted and compared from Day 1 and Day 9, showing two distinct peaks of the viral load. The following image shows those two peaks during Paxlovid treatment:

The author concludes that their findings suggest early treatment with Paxlovid “may transiently suppress viral replication before natural immunity is sufficient to complete the clearance of SARS-CoV-2.” 

Post-Paxlovid Rebound Was Demonstrated in Pfizer Trials

The post-Paxlovid rebound phenomenon is not so surprising as it was observed by Pfizer in their clinical trial. Pfizer reported this data to the FDA review to approve it for emergency use. This information was briefly included on the 23rd page of the FDA document,8 stating the following:

Several subjects appeared to have a rebound in SARS-CoV-2 RNA levels around Day 10 or Day 14, although this occurred among subjects with or without potential resistance-associated substitutions detected at Day 1 or Day 5.”

Just as seen in the pre-print image above, the same is shown in the following image from the FDA review document. As you can see, the lines suddenly shift in an upward trend between Days 10-14, representing the rebound or COVID relapse.

Though this phenomenon was reported to the FDA for review, the rebound information was not included in Pfizer’s New England Journal of Medicine paper, and therefore, was not made readily available to the public .9


Post-Paxlovid COVID rebound or relapse is now a documented phenomenon that is occurring among some people. While we know this occurs, there is much unknown. Pending the government’s investigation into this phenomenon, questions remain:

  • How often does relapse occur?

  • Does Paxlovid blunt the natural immune response?

  • Are relapsed patients contagious during the second peak?

  • Does resistance develop to Paxlovid?

  • Should high risk individuals with relapse be treated again?

  • What is the long-term safety?

We know that early treatment is critical when it comes to COVID, but does early treatment with Paxlovid come at a cost?







  7. HTTPS://ASSETS.RESEARCHSQUARE.COM/FILES/RS-1588371/V1/48342D2C-B3EA-4228-B600-168FCA1FDED7.PDF?C=1650977883


  9. HTTPS://WWW.NEJM.ORG/DOI/FULL/10.1056/NEJMOA2118542’